Page results
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
This page offers advice to patients who are feeling sick.
-
This page has been written by the Department of Neuroradiology at the National Hospital for Neurology and Neurosurgery (NHNN). Our aim is to provide you with information about endovascular treatments…
-
“No one is invulnerable” – stark messages from patients and staff about the realities of coronavirus
The enormous pressure our staff are under was the focus of a powerful BBC News report about the surge in Covid-19 cases broadcast on Wednesday 6 January.
File results
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment